Fullcircle Wealth LLC Has $381,000 Holdings in Becton, Dickinson and Company $BDX

Fullcircle Wealth LLC boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 103.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 2,129 shares of the medical instruments supplier’s stock after acquiring an additional 1,084 shares during the quarter. Fullcircle Wealth LLC’s holdings in Becton, Dickinson and Company were worth $381,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock valued at $2,880,510,000 after purchasing an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after purchasing an additional 312,124 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Becton, Dickinson and Company by 0.4% in the second quarter. Nordea Investment Management AB now owns 3,365,509 shares of the medical instruments supplier’s stock valued at $577,420,000 after purchasing an additional 12,602 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on BDX. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Argus upped their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $205.40.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 1,895 shares of company stock valued at $358,995 in the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.8%

Shares of BDX opened at $177.20 on Tuesday. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The stock has a market capitalization of $50.79 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a fifty day moving average of $188.03 and a 200-day moving average of $182.77.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.